A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies

Summary

To determine MTD and DLT of ABI-010 given weekly every three weeks followed by one week of rest (Cycle 1). Determine MLD and DLT in combination with ABI-007; to characterize the toxicities of ABI-010 alone and in combination with ABI-007.

Timeline

Start

2012-04-01

Primary completion

2013-04-01

Completion

2014-04-01

Drugs

Indications